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Abbreviations 
α5-GABAARs = α5 subunit containing GABAA receptors  
BW= body weight 
CI = Confidence interval 
CNS = central nervous system 
eIPSC = electrically evoked inhibitory postsynaptic current 
fEPSP = field excitatory postsynaptic potential.  
GABA = Gamma-aminobutyric acid 
GABAARs. = GABAA receptors 
LTP = long term potentiation 
mIPSC = miniature inhibitory postsynaptic current 
NAM = Negative allosteric modulator. 
sIPSC = spontaneous inhibitory postsynaptic current 
TBS = theta burst stimulus. 
TE = total number of errors 
TTX = tetrodotoxin 
Vh = holding potential 
WT = wild type 
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Abstract 
In the mammalian central nervous system (CNS) GABAA receptors (GABAARs) mediate 
neuronal inhibition and are important therapeutic targets. GABAARs are composed of 5 
subunits, drawn from 19 proteins, underpinning expression of 20-30 GABAAR subtypes. In 
the CNS these isoforms are heterogeneously expressed and exhibit distinct physiological 
and pharmacological properties. We report the discovery of S44819, a novel tricyclic 
oxazolo-2,3-benzodiazepine-derivative, that selectively inhibits α5-subunit-containing 
GABAARs (α5-GABAARs). Current α5-GABAAR inhibitors bind to the “benzodiazepine site”. 
However, in HEK293 cells expressing recombinant α5-GABAARs, S44819 had no effect on 
3H-flumazenil binding, but displaced the GABAAR agonist 3H-muscimol and competitively 
inhibited the GABA-induced responses. Importantly, we reveal that the α5-subunit 
selectivity is uniquely governed by amino acid residues within the α-subunit F-loop, a region 
associated with GABA binding. In mouse hippocampal CA1 neurons, S44819 enhanced 
long-term potentiation (LTP), blocked a tonic current mediated by extrasynaptic α5-
GABAARs, but had no effect on synaptic GABAARs. In mouse thalamic neurons, S44819 
had no effect on the tonic current mediated by δ-GABAARs, or on synaptic (α1β2γ2) 
GABAARs. In rats, S44819 enhanced object recognition memory and reversed 
scopolamine-induced impairment of working memory in the eight-arm radial maze. In 
conclusion, S44819 is a first in class compound that uniquely acts as a potent, competitive, 
selective antagonist of recombinant and native α5-GABAARs. Consequently, S44819 
enhances hippocampal synaptic plasticity and exhibits pro-cognitive efficacy. Given this 
profile, S44819 may improve cognitive function in neurodegenerative disorders and facilitate 
post-stroke recovery. 
 
Key Words: 
Tonic inhibition; phasic inhibition; α5-GABAA receptors; extrasynaptic GABAA receptors; 
long term potentiation; cognition. 
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Highlights:  
 
All current, selective, inhibitors of α5-GABAARs bind to the “benzodiazepine site”. 
 
S44819 acts via a unique site on the α5-GABAAR to competitively inhibit GABA binding.  
 
S44819 inhibits mouse hippocampal tonic, but not phasic inhibition & facilitates LTP. 
 
In rats S44819 enhanced novel object recognition & spatial working memory. 
 
This novel α5-GABAAR site offers a new target to treat cognitive disorders & stroke. 
 
S44819 has successfully completed a phase1 clinical trial. 
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1. INTRODUCTION 
1.1) GABAA receptors. Gamma-aminobutyric acid (GABA) is a major inhibitory 
neurotransmitter in the mammalian central nervous system (CNS), that influences neuronal 
activity by activating ionotropic anion-conducting GABAA receptors (GABAARs) and 
metabotropic GABAB receptors (Olsen and Sieghart, 2008; Rudolph and Möhler, 2014). 
GABAARs are members of the Cys-loop ligand-gated ion-channel family, which are 
composed of five subunits, assembled from a repertoire of 19 proteins (Olsen and Sieghart, 
2008). This diversity underpins the expression of 20-30 GABAAR subtypes, which exhibit 
distinct physiological and pharmacological properties (Olsen and Sieghart, 2008; Rudolph 
and Möhler, 2014). The topographical CNS distribution of GABAAR subunits suggests non-
redundant functions (Fritschy and Panzanelli, 2014; Pirker et al., 2000; Wisden et al., 1992) 
and by inference, drugs that exhibit GABAAR isoform selective actions may present a 
behavioural profile distinct from that of non-selective agents. In support, mice genetically 
engineered to express benzodiazepine-insensitive α-subunits revealed that the diverse 
behavioural effects of diazepam are attributed to receptors incorporating particular α-
subunits (Rudolph and Möhler, 2014). 
1.2) α5-GABAA receptors: physiology & pharmacology. Of interest here are GABAARs 
incorporating the α5 subunit (α5-GABAARs). In humans, PET imaging studies with Ro15-
4513 suggest α5-GABAARs to be expressed in hippocampus, cortex and ventral striatum 
(Mendez et al., 2013). In rodents this receptor is expressed in cortex, amygdala, olfactory 
bulb and spinal cord, but is particularly densely expressed in the hippocampus (Rudolph 
and Mohler, 2014). In the rodent hippocampus, α5-GABAAR are located primarily, but not 
exclusively, extra-synaptically, where in CA1 pyramidal neurons they mediate tonic 
inhibition and contribute to occasional slow inhibitory phasic events (Capogna and Pearce, 
2011; Caraiscos et al., 2004; Prenosil et al., 2006; Zarnowska et al., 2009). Mice lacking the 
α5 subunit exhibit an enhanced performance in various cognitive tasks (Atack, 2011; Martin 
et al., 2009; Rudolph and Möhler, 2014), although present with an impairment of executive 
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function (assessed by a puzzle box test) and short-term memory (Zurek et al., 2016).In 
rodents, selective benzodiazepine-site α5-GABAAR negative allosteric modulators (NAMs) 
reduce the CA1 tonic current and display pro-cognitive activity in certain behavioural 
paradigms (Atack, 2011). The expression of hippocampal α5-GABAARs is dynamic e.g. 
being altered by inflammatory cytokines and in mouse models of Alzheimer’s disease, a 
plasticity associated with impaired memory performance (Wang et al., 2012; Wu et al., 
2014). Due to their therapeutic potential in treating moderate cognitive impairment (Atack, 
2011) and improving recovery from stroke (Clarkson et al., 2010), there is considerable 
interest in developing drugs that selectively inhibit α5-GABAAR function (Atack, 2011; 
Bolognani et al., 2015; Darmani et al., 2016). 
All current selective α5-GABAAR inhibitors bind to the benzodiazepine recognition site, 
located between the α5 and γ2 subunit interface, where they act as NAMs, to reduce GABA 
efficacy (Rudolph and Möhler, 2014). We reported the synthesis and partial biological 
characterization of a family of tricyclic compounds based on an oxazolo-2,3-benzodiazepine 
scaffold (Ling et al., 2012; Ling et al., 2015). In contrast to classical 1,4-benzodiazepines, 
e.g. diazepam and to current α5-GABAAR NAMs, these compounds are orthosteric 
inhibitors of GABA binding, acting at the α-β subunit interface. For some compounds this 
property is paired with inhibition of channel gating, similar to the properties of the GABAAR 
antagonist bicuculline (Ueno et al., 1997). Here, we demonstrate that a new member of this 
series, S44819, is potentially the most valuable. S44819 is an orthosteric, competitive, α5-
GABAAR-selective antagonist. Distinct from known α5-GABAAR NAMs, the α-subunit 
specificity is governed by amino acid residues located in the α5-subunit F-loop, a region 
associated with GABA binding. In contrast to bicuculline, S44819 has no effect on the 
activation of α5-GABAARs by etomidate. In CA1 pyramidal neurons, S44819 selectively 
blocked the tonic current mediated by extrasynaptic α5-GABAARs, with no effect on the 
phasic currents mediated by synaptic GABAARs and consequently enhanced submaximal 
long-term potentiation (LTP). Further emphasising selectivity, in ventrobasal (VB) thalamic 
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neurons, S44819 had no effect on the tonic or phasic conductance mediated by 
extrasynaptic δ-GABAARs and synaptic α1β2γ2-GABAARs (Belelli et al., 2005).  
Although acting on the receptor in a manner distinct from established α5-GABAAR NAMs, in 
common, in rats S44819 enhanced object recognition memory and reversed scopolamine-
induced impairment of spatial working memory in the eight-arm radial maze. Therefore, 
S44819 provides a new mechanistic tool to elucidate the role of α5-GABAARs in neuronal 
signalling and behaviour. Given this profile S44819 has recently undergone a successful 
phase 1 clinical trial (Darmani et al., 2016).  
 
2. MATERIALS AND METHODS 
2.1) Compounds. 
S44189 (Egis-13529), a substituted 8-methyl-5-[1-benzothiophen-2-yl]-1,9-dihydro-2H-
[1,3]oxazolo[4,5-h][2,3]benzodiazepin-2-one, was produced at greater than 97% purity at 
Egis Pharmaceuticals PLC as previously described (Ling et al., 2012; Ling et al., 2015). All 
chemical and biochemical reagents were of the highest grade available. For all in vitro 
experiments a stock solution of S44819 (10 mM) was dissolved in 100% DMSO aliquoted 
and stored at -20 °C. Note that for the in vitro assays 0.1 % DMSO had no effect on the 
various control recordings made. For all in vivo studies a nano-encapsulated preparation of 
S44819 was used The S44819 (1% w/w) was dispersed with Lipoid S100 (10% w/w Lipoïd 
GmbH, Ludwigshafen, Germany) and Trehalose (15% w/w) in water. The suspension was 
stirred for 3h at 50 °C and homogenized with an Ultraturax T25 digital at 20,000 rpm 
during 2 min 30 s. The milling of the suspension was then performed with 50ml of zirconium 
oxide beads at 5,000 rpm during 90 min with a DynoMill RL equipment. The particle size 
was measured during the milling by laser diffraction and/or dynamic light scattering (DLS). 
At the end of the process a filtration of the suspension was performed with 25 µm filters. 
The particle size obtained was D(50, v) = 130 nm. In order to prevent crystal growth and 
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particle agglomeration, the suspension was then freeze-dried. Control experiments used the 
vehicle (Lipoïd S100/trehalose, 40%/60%, w/w). 
 
2.2) Cell culture.  
HEK293 cell lines, stably expressing recombinant GABAARs were obtained upon 
transfection with the cDNAs encoding the human α-subunit isoforms, together with the 
cDNAs for rat β2 (short) and rat γ2 (long) in antibiotic resistance variants of the expression 
vector pcDNA3.1 (Life Technologies, Inc., Carlsbad, CA, USA), or pExchange (Agilent 
Technologies, Inc., Santa Clara, CA, USA) as previously described (Ling et al., 2015). The 
GABAAR αxβ2γ2 cell lines were maintained under triple antibiotic selection with neomycin 
(0.6 mg/ml), zeocin (0.2 mg/ml) and puromycin (3 µg/ml) in Dulbecco’s DMEM 
supplemented with 10 v/v% foetal bovine serum and 10 mM KCl. Further cell lines, one co-
expressing GABAAR β2- and γ2-subunits, another expressing the γ2-subunit were 
propagated under selection with neomycin (0.6 mg/ml) and zeocin (0.2 mg/ml), or zeocin 
(0.2 mg/ml), respectively, in Dulbecco’s DMEM supplemented with 10 v/v% foetal bovine 
serum. 
Transient transfections were made with the calcium-phosphate method (Salmon and Trono, 
2006) utilising the desired expression vectors of the requisite wild-type (WT) and variously 
mutated α-subunit cDNAs for functional studies. The cells were collected 48 h later, 
aliquoted and frozen in foetal bovine serum supplemented with 10% (v/v) DMSO and stored 
at -150°C until further use.  
 
2.3) Site-directed mutagenesis.  
Mutations were introduced by site-directed mutagenesis with custom-designed primers 
using Phusion High-Fidelity DNA Polymerase (Thermo Fisher Scientific Waltham, MA USA) 
as per the manufacturer’s instructions. The resultant constructs were verified by DNA 
sequencing of the entire coding region (Biomi Ltd, Gödöllő, Hungary). 
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2.4) FLIPR dye assay. 
For fluorescence recordings, cells were plated in black, clear-bottom, half-volume 96-well 
plates coated with poly-D-lysine at 50,000 cells per well in 50 µl of growth medium 
containing neomycin, zeocin and puromycin and used 24 h later. Briefly, the cells were 
washed and incubated at 37°C in 20 mM HEPES buffered Hank’s Balanced Salt Solution 
(HBSS), pH 7.4 supplemented with FLIPR Membrane Potential Assay Kit BLUE (Molecular 
Devices) dye at 2× dilution. The dye solution contains a voltage-sensitive fluorescent dye 
and an extracellular fluorescence quench-substance. Simultaneously with dye-loading, 
various concentrations of the test compound dissolved in HBSS supplemented with 20 mM 
HEPES, pH 7.4 and 1% (v/v) DMSO were added to the incubation medium at 37 °C. The 
final concentration of DMSO in the medium was 0.1% (v/v). Forty minutes later the plates 
were placed into a Flexstation3 (Molecular Devices) plate reader and the recording of 
fluorescence commenced — designated as time 0. Subsequently, the fluorescence signal 
was sampled at 2 s intervals, the stimulus (GABA, or etomidate) was introduced at 30 s and 
the recording was terminated at 120 s after time 0. The area under the curve of time vs. 
relative fluorescence units after the addition of agonist was calculated with the average 
baseline subtracted by Soft-Max 5.4 software and used for further analysis. Non-linear 
regression curves were fitted using GraphPad Prism version 6.0 and the EC50, or IC50 
values were derived from fit to the curve. If otherwise not indicated, to make the data 
comparable between experiments, the results are expressed as a percentage of the 
response evoked by 1.6 µM GABA. 
 
2.5) Radioligand-binding studies. 
HEK-293T (ACC 635) cells were transfected with the calcium-phosphate co-precipitation 
method (Salmon and Trono, 2006) with cDNAs encoding the GABAAR human α5, human 
β3, rat γ2 (long) subunits in the expression vector pcDNA3.1 (Life Technologies, Inc., 
Carlsbad, CA, USA) and pExchange (Agilent Technologies, Inc., Santa Clara, CA, USA) 
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(Ling et al., 2015). The β3 subunit was used in binding assays of α5 subunits, as GABAA 
receptor binding was much greater than with β2 subunits — see also (Lüddens et al., 1994). 
Cells were harvested and frozen 72 h later. All other procedures assessing the binding of 
3H-muscimol and 3H-flumazenil to crude membranes prepared from the transfected cells 
were as previously reported (Ling et al., 2015). 
 
2.6) Whole-cell voltage-clamp studies of recombinant GABAARs expressed in HEK 
293 cells. 
 
Patch electrodes were filled with a solution comprising (in mM) 140 CsCl, 0.1 CaCl2, 1.1 
EGTA, 10 HEPES, pH 7.2 (adjusted with1 M CsOH). Whole-cell currents (Vh = -60 mV) 
evoked by the local brief pressure-application (General Valve Picospritzer II) of GABA 
(100µM; one application of 50 ms duration per min) were recorded in an extracellular 
solution consisting of (in mM) 142.8 NaCl, 0.1 MgCl2, 0.1 CaCl2, 10 glucose, 10 HEPES, 
pH 7.2 (adjusted by 1 M NaOH). Three control GABA-evoked currents of amplitudes 
within 10% of each other were obtained before perfusing S44189 from a reservoir into the 
recording chamber. 
2.7) Preparation of mouse hippocampal and thalamic brain slices for whole-cell 
voltage-clamp studies. 
Hippocampal, or thalamic brain slices were prepared from mice of either sex (p 17 – 24) 
as we previously described (Brown et al., 2016; Herd et al., 2008). Animals were killed by 
cervical dislocation in accordance with Schedule 1 of the UK Animals (Scientific 
Procedures) Act 1986. The brain was rapidly dissected and placed in ‘ice-cold’, 
oxygenated artificial cerebrospinal fluid (aCSF-1) solution (in mM): 225 - 234 sucrose, 
2.95 KCl, 1.25 NaH2PO4, 26 NaHCO3, 0.5 CaCl2, 10 MgSO4, 10 d-glucose, (pH 7.4; 330 – 
340 mosmol l−1). Hippocampal coronal slices (300 µm thick) were cut using a Vibratome 
(Leica VT1000), transferred onto a nylon mesh platform housed within a chamber 
containing an oxygenated aCSF-2 composed of (in mM): 126 NaCl, 2.5 KCl, 26 NaHCO3, 
1.25 NaH2PO4, 0.5 CaCl2, 10 d-glucose, 10 MgSO4, 1 ascorbic acid and 3 Na pyruvate 
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(pH 7.4; 300–310 mosmol l−1; room temperature), where they were maintained for a 
minimum of 1 h prior to experimentation. For thalamic slices, the brain was again 
maintained in the oxygenated aCSF-1 solution and then sectioned in the horizontal plane 
using a Vibratome series 1000 PLUS Sectioning System (Intracell, Royston, Hertfordshire, 
UK). Tissue slices were cut at 300 - 350 µm thickness and then transferred to a chamber 
containing oxygenated aCSF-3 solution (in mM: 126 NaCl, 2.95 KCl, 26 NaHCO3, 1.25 
NaH2PO4, 2 CaCl2, 2 MgCl2, 10 glucose (pH 7.4; 306–309 mosmol l−1; room temperature) 
for a minimum of 1 h before recording. 
 
2.8) Whole-cell voltage-clamp recordings:  
The extracellular recording solution (ECS) contained (in mM): 126 NaCl, 2.95 KCl, 26 
NaHCO3, 1.25 NaH2PO4, 2 CaCl2, 10 d-glucose, 2 MgCl2, (pH 7.4; 300–310 mosmol l−1). 
Recording electrodes were constructed from thick-walled borosilicate glass (Garner Glass 
Co., Claremont, CA, USA), using a PC-10 electrode puller (Narashige, Japan) and had 
open tip resistances of 3 – 6 MΩ when containing either intracellular solution-1 (ICS-1) for 
CA1 neurons comprising (in mM): 135 CsCl, 10 Hepes, 10 EGTA, 2 Mg-ATP, 1 CaCl2, 1 
MgCl2, 5 QX-314 (pH 7.3 with CsOH, 300–305 mosmol l−1), or ICS-2 for thalamocortical 
neurons (in mM): 140 CsCl, 10 Hepes, 10 EGTA, 2 Mg-ATP, 1 CaCl2, 2 MgCl2, 5 QX-314 
(pH 7.2 – 7.3 with CsOH, 290- -300 mosmol l−1. For CA1 recordings the hippocampal 
slices were incubated in vigabatrin (50 µM; Sigma Aldrich) for at least 1 h prior to 
recording to raise the ambient extracellular concentration of GABA (Caraiscos et al., 
2004). 
Recordings were made at 35°C from hippocampal CA1 pyramidal neurons, or thalamic 
ventrobasal (VB) neurons visually identified with an Olympus BX51 (Olympus, Southall, 
UK) microscope equipped with differential interference/infrared optics and a CCD camera. 
Whole-cell voltage-clamp recordings were acquired at a holding potential (Vh) of -60 mV 
using an Axopatch 1D amplifier (Molecular Devices, Sunnyvale, CA, USA). Data 
acquisition and digitization (10 kHz) was performed using a NIDAQmx interface (National 
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Instruments, Austin TX, U.S.A.). For both VB and CA1 neurons the mIPSCs were isolated 
by supplementing the ECS with 2 mM kynurenic acid and 0.5 µM tetrodotoxin (TTX). The 
mIPSC amplitude was determined as previously described (Brown et al., 2015). A putative 
effect of S44819 on the mIPSC amplitude was assessed in paired recordings using the 
paired t test. The tonic current was calculated by determining the outward current 
produced by bath applied bicuculline methobromide (30 µM) – (Brown et al., 2015). The 
effect of S44819 (10 µM) on the holding current was similarly determined. In quantifying 
the holding current the mean DC current of a 30 – 60 s current section was determined 
from sequential 25.6 – 102.4 ms epochs, depending on the mIPSC frequency. All epochs 
containing mIPSCs, or sections of recordings that were unstable, were not included in the 
determination of the mean holding current (Brown et al., 2015). 
 
2.9) Preparation of mouse hippocampal brain slices for extracellular recording. 
The hippocampal brain slices were obtained from 2 to 4 month old male C57/Bl6 mice and 
prepared as we previously described (Zhang et al., 2013). The mice were killed by 
cervical dislocation in accordance with Schedule 1 of the UK Government Animals 
(Scientific Procedures) Act 1986. After decapitation, the brain was dissected, before being 
incubated in a chamber containing artificial cerebrospinal fluid (aCSF) composed of (in 
mM): NaCl 124; NaHCO3 26; NaH2PO4 1.25; KCl 3; CaCl2 2; MgSO4 1; D-glucose 10; pH 
7.4, when supplied with 95% O2/ 5% CO2. The brain was then bisected and glued to a 
metal plate with the mid-line uppermost and horizontal. The mounted tissue was then 
submerged in oxygenated (95% O2/ 5% CO2) aCSF, before being cut into 400 µm sagittal 
hippocampal slices by a Vibratome (IntraCel, Royston, Herts, UK). Such slices were then 
maintained in an incubation chamber containing circulating oxygenated aCSF (room 
temperature) on a submerged nylon mesh, for at least 1 h prior to use. 
 
2.10) Extracellular recording from hippocampal CA1 pyramidal neurons. 
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The recording conditions were as we previously described (Zhang et al., 2013). The 
hippocampal slice was submerged in recording chamber (Scientific Systems Design Paris 
France), perfused (4 – 6 ml min-1; oxygenated 95% O2/ 5% CO2), with aCSF maintained at 
32oC by a Digitimer PTC03 temperature controller. To induce basal field excitatory 
postsynaptic potentials (fEPSPs) a stimulating tungsten bipolar electrode (~100 µM 
diameter) was located within the stratum radiatum, and a Digitimer stimulator (0.033 Hz; 
100 µs duration) used to excite the afferent Schaffer collateral-commissural pathway from 
the CA3 area to the CA1 region. A glass (King Precision Glass ID = 1.0 ± 0.05 µm; OD = 
1.55 ± 0.05 µm) extracellular recording electrode was filled with aCSF (< 5 MΩ) and 
carefully lowered into stratum radiatum dendritic region of CA1 until clear fEPSPs were 
evident. The signal was amplified by a Warner Instruments Corp. differential amplifier with 
the fEPSPs simultaneously displayed on a digital storage oscilloscope (Tektronix 2201) and 
on a computer screen via an A to D converter (National Instruments, Paris, France; BNC-
2090). The stimulus parameters, the acquisition and the analysis of fEPSPs was controlled 
by an LTP software suite (provided by Professor Collingridge and Dr. Anderson; Bristol 
University U.K.). The slope (mV ms-1) and amplitude (mV) of each fEPSP was calculated on 
line and the stimulus adjusted to produce a response 40% of the maximum. All fEPSPs 
were acquired at 10 kHz and filtered at 10 Hz to 3 kHz.  
To investigate the ability of S44819 to induce repetitive firing, in response to a single 
electrical stimulus of the Schaffer collateral pathway, fEPSPs (elicited at 0.033 Hz, 0.1 ms 
duration) were recorded for 10 min to establish consistent controls before the bath perfusion 
of S44819, or bicuculline. To induce long term potentiation (LTP) a maximal 4 pulse, or 
submaximal 3 pulse theta-burst (TBS) stimulation protocol was employed. The duration of 
each single stimulation = 0.1 ms, which was delivered in a group of 4 or 3 pulses at a 
frequency of 100 Hz, repeated 10 times with an interval of 200 ms between each of the 10 
clusters of 4, or 3 pulses) – see (Zhang et al., 2013). and assessment of the magnitude of 
LTP was made by taking the mean of the fEPSP slopes for each slice between 50 – 60 min 
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post the TBS. Statistical analysis of LTP was performed with SPSS software employing a 
one-way ANOVA followed by a post hoc Tukey HSD multiple comparison test. 
 
2.11) Object recognition assay in rats. 
Male Sprague-Dawley (SPRD) rats bred in house were used at 290-350 g body weight 
(BW). All animals were housed under standard laboratory conditions (24 ± 2 ºC, 40–60% 
relative humidity), on a 12-h light/dark cycle with light onset at 6:00 am (Initial Zeitgeber 3). 
All experimental protocols were approved by the Animal Care and Use Ethical Committee of 
Egis Pharmaceuticals PLC and complied with the Hungarian Law of Animal Care and Use 
(1998. XVIII). The object recognition protocol was as previously described (Gacsályi et al., 
2013). Briefly, on day 0 (familiarization) the test animals were placed in the test box one 
by one for 2.5 min each. On the next day, animals were placed in the test box to explore 
two identical objects 120 min after p.o. administration of either nano-encapsulated S44819 
consisting of S44819 3.8/Lipoïd S100 (Lipoïd GmbH, Ludwigshafen, Germany) 
38.5/trehalose 57.7, w/w/w) corresponding to S44819 (0.1, 0.3 and 1mg/kg), or the vehicle 
(Lipoïd S100/trehalose, 40%/60%, w/w). The animal was returned to its home cage once 
the exploration times of both objects reached 10 sec/object within a cut-off time of 5 min 
(acquisition). The amount of time spent exploring the arena and the time of investigative 
contact with each object was recorded. Twenty-four hours later, rats were allowed to 
explore the familiar object and a new object in the place of the second familiar one in the 
same arena. The timings of the test were adjusted so that vehicle-treated animals did not 
discriminate between the familiar and the new object 24h after the first trial. The calculated 
parameter was the discrimination index: DI = [Exploration time of new object in seconds (N) 
- Exploration time of familiar object in seconds (F)]/[ exploration time of new object in 
seconds (N) + Familiar object exploration time in seconds (F)]; DI=[N-F]/[N+F]. One-way 
ANOVA was used to analyse the effect of treatment with S44819 on object recognition 
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performance, followed by Dunnett’s test for multiple comparisons. All analysis was by 
GraphPad Prism v6.0 (GraphPad Software, San Diego, USA).  
 
 
2.12) Working memory in eight-arm radial maze in rats.  
 
Male Sprague Dawley (SPRD) rats (Charles River, Germany and Egis Pharmaceuticals 
PLC, Hungary), (240-310 g BW) were trained and tested in an eight-arm-maze-based 
spatial working memory task (Gacsályi et al., 2013). Upon partial restriction of food 
(receiving approximately 8-10 g standard rodent food/day/animal), the rat was rewarded by 
bait when it entered a previously unvisited arm of the maze. Training took place once a day 
for three weeks. The total number of errors (TE) and the number of correct entries until the 
first mistaken choice (ICR) were recorded. Animals included in the study had TE values < 3 
and ICR ≥ 7. The testing of the compound was on the last day of the experiment. 
Scopolamine hydrobromide (0.25 mg/kg), or saline were injected s.c., immediately followed 
by the i.p. administration of either S44819 (1 and 3 mg/kg), or vehicle (0.4 % methyl 
cellulose w/v) 30 min before the start of the test. A single trial lasted a maximum of 5 min. 
The test was validated by comparing the vehicle/vehicle treated group with the group 
receiving scopolamine/vehicle by Mann-Whitney U-test. The effect of S44819 was analysed 
by non-parametric Kruskal-Wallis ANOVA, post-hoc comparisons were performed using the 
Dunn’s multiple comparisons test. 
 
3. RESULTS 
3.1) S44819 is a competitive inhibitor of recombinant α5-GABAARs. 
The FLIPR assay revealed a potent inhibition by S44819 (1 nM – 10 µM) of the GABA-
induced response (a change in fluorescence considered to report cellular depolarisation) 
mediated by recombinant α5β2γ2 GABAARs expressed in HEK293 cells (Figure 1A). 
S44819 exhibited a preference for the α5-GABAAR subtype, requiring greater 
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concentrations to inhibit equivalent GABAARs incorporating the α1, or the α3 subunit, with 
little effect on GABA-evoked responses mediated by α2-GABAARs, until the relatively high 
concentration of 30 µM. (Figure 1A, Table 1). Further studies with α5-GABAARs 
demonstrated that increasing concentrations of S44819 (100 nM – 10 µM) caused a parallel 
shift to the right of the GABA concentration-response relationship (Figure 1B), producing 
linear Schild-plots with a slope not significantly different from unity (not shown), suggesting 
that S44819 is a competitive α5-GABAAR antagonist (Kb = 221 nM - geometric mean, 95% 
Confidence Interval [CI] 167 to 294, n = 7). In contrast, inhibition of α1β2γ2
 
and α3β2γ2
 
GABAARs by S44819 could not be classified by Schild-analysis.  
Etomidate activates GABAARs via a mechanism distinct from GABA. In contrast to the 
potent inhibitory effects upon GABA-activated responses mediated by α5-GABAARs, 
S44819 (up to 3 µM) had no effect on the etomidate (30 µM)-evoked response. Consistent 
with previous reports, gabazine was similarly ineffective in blocking such responses, 
whereas they were inhibited by bicuculline in a concentration-dependent manner 
(Thompson et al., 1999; Ueno et al., 1997) (Figure 2). 
To further characterize the interaction of S44819 with the GABA binding-site, we 
investigated the influence of S44819 on the binding of the GABAAR agonist 3H-muscimol. 
S44819 (0.1 nM – 100 µM) produced a concentration-dependent displacement of the 
specific binding of 3H-muscimol to membrane suspensions made from HEK293 cells 
previously transfected with α5, β3 and γ2 subunits (Ki= 66 nM geometric mean, 95% CI. 
61 to 72, n = 3), further supporting an interaction of the compound with the GABA 
recognition site of the receptor (Figure 3A). In contrast, S44819 (0.1 nM – 10 µM) had no 
effect on the specific binding of the benzodiazepine site ligand 3H-flumazenil to α5-
GABAARs (α5β3γ2), whereas, the benzodiazepine-site α5-GABAAR-selective NAM 
Ro4938581 (Knust et al., 2009), produced the expected concentration-dependent 
inhibition with a Ki of 13 and 12.2 nM in two independent studies (Figure 3B). 
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3.2) Location of the S44819 binding site on the α5-GABAAR. 
The properties of the α5-GABAAR inhibitory effect of S44819 appeared to conform to a 
loop-F model of action (Ling et al., 2015; Mihalik et al., 2017). First, the compounds require 
strict regiochemistry of the oxazolone moiety to interact with amino acid residues previously 
reported to interact with GABA (Ling et al., 2015; Mihalik et al., 2017). A further facet of the 
loop-F model is that the pharmacological properties of this class of compounds are 
determined by the variable, N-terminal segment of loop-F of the α-subunit (Mihalik et al., 
2017). However, the impact of loop-F alterations on the inhibitory effect varied both with the 
compound and the α-subunit tested (Mihalik et al., 2017). For S44819, the potent inhibitory 
effect on the GABA-induced change in fluorescence mediated by wild type (WT) α5-
GABAARs was greatly reduced for equivalent receptors incorporating a mutant α5 subunit 
(α5-LFα2) engineered to express the α2 T---TYNASD----P loop-F sequence, which replaced 
the native α5 V----NGSTK----E loop-F sequence (Figure 4). These observations were 
corroborated by complementary whole-cell voltage-clamp experiments, performed using 
HEK 293 cells (Vh = -60 mV), previously transfected with recombinant GABAAR subunits. 
Here, a relatively low concentration of S44819 (30 nM) decreased the GABA-evoked 
current (100 µM GABA transiently applied by pressure application once per 30 s for 50 ms 
from a local pipette) mediated by α5-GABAARs to 32 ± 4% of control; n = 3; Figure 5). In 
contrast, S44819 (30 nM) had no effect on equivalent α2-GABAARs (92 ± 8% of control; n = 
3, Figure 5). The potent and selective inhibition by S44819 of GABA-evoked currents 
mediated by α5-GABAARs was completely prevented for GABA-evoked responses 
mediated by the mutant (α5-LFα2) subunit containing receptor (100 ± 4% of control; n = 3), 
in this regard mimicking the lack of effect of this compound on equivalent α2-GABAARs (92 
± 8% of control; n = 3) under these conditions (Figure 5).  
 
3.3) S44819 selectively inhibits extrasynaptic α5-GABAARs of mouse CA1 pyramidal 
neurons. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 18
Given the selectivity of S44819 for recombinant α5-GABAARs we investigated whether a 
similar specificity was evident for neuronal receptors. We previously demonstrated that 
mouse CA1 pyramidal neurons exhibit a tonic current mediated by α5-GABAARs 
(Caraiscos et al., 2004). Here, we used the whole-cell voltage-clamp technique to record 
the tonic and phasic currents (i.e. the mIPSCs) mediated by extrasynaptic α5-GABAARs 
and by synaptic GABAARs respectively. Using a hippocampal slice preparation recordings 
were made from CA1 pyramidal neurons (Vh = -60 mV), pre-incubated in the GABA-
transaminase inhibitor vigabatrin (50 µM) for 2 - 4 h to raise extracellular levels of GABA 
and thereby enhance the tonic current mediated by α5-GABAARs (Caraiscos et al., 2004). 
Under these conditions, the bath perfusion of S44819 (10 µM) induced an outward current 
(80 ± 20 pA; n = 3) - Figure 6A,C. Note the subsequent perfusion of bicuculline (30 µM) to 
these neurons only produced a relatively small further outward current of 19 ± 5 pA (n = 
3), suggesting S44819 at this concentration in the slice to be a nearly full α5-GABAAR 
inhibitor (Figures 6A, C). We deliberately used a relatively large concentration of S44819 
to investigate the selectivity of the drug for extrasynaptic vs synaptic GABAARs in CA1 
neurons. Inspection of the recordings revealed the mIPSCs to remain clearly evident in 
the presence of S44819 (10 µM), whereas these phasic inhibitory events were abolished 
by the subsequent addition of bicuculline (30 µM) – see Figure 6A. These observations 
suggest that in contrast to bicuculline, S44819 selectively inhibits the extrasynaptic α5-
GABAARs, with little, or no effect on their synaptic counterparts. In confirmation of this 
selectivity, in paired recordings S44819 (10 µM) had no significant effect on the mIPSC 
amplitude (control = -72 ± 4 pA; S44819 = -64 ± 2 pA; paired t test p = 0.095; n = 5) – 
Figure 6B, D. 
 
3.4) S44819 had no effect on the extrasynaptic α4β2δ GABAARs, or synaptic α1β2γ2 
GABAARs of mouse thalamic ventrobasal neurons. 
We next explored whether S44819 had any effect on a tonic current known to be 
mediated by non-α5-GABAA extrasynaptic receptors. Our previous studies revealed the 
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tonic current of ventrobasal (VB) thalamic neurons to be mediated by GABAARs 
composed of α4, β2 and δ subunits (Belelli et al., 2005; Brown et al., 2015; Herd et al., 
2013; Peden et al., 2008). In contrast to the CA1 neurons, S44819 (10 µM) had no effect 
on the holding current (Vh = -60 mV) of VB neurons, whereas the subsequent addition of 
bicuculline (30 µM) produced the expected outward current (n = 4; Figure 7A, C). By 
postnatal day 20 we have shown the phasic inhibitory currents (i.e the mIPSCs) of VB 
neurons to be mediated by synaptic GABAARs composed of α1, β2 and γ2 subunits 
(Belelli et al., 2005; Peden et al., 2008). In common with the CA1 neurons, in paired 
recordings S44819 (10 µM) had no effect on the mIPSC amplitude (control = -74 ± 4 pA; 
S44819 = -73 ± 4 pA; n = 4; p = 0.855, paired t-test), of P20 VB neurons (Figures 7 B, D). 
 
3.5) The α5-GABAAR antagonist S44819 does not produce repetitive firing, but does 
enhance hippocampal CA1 LTP. 
Non subtype-selective GABAAR antagonists such as picrotoxin and bicuculline are known 
to be pro-convulsant. Having demonstrated that S44819 selectively blocked GABA-ergic 
tonic, but not phasic inhibition of CA1 neurons we recorded field excitatory postsynaptic 
potentials (fEPSPs) from mouse CA1 neurons to compare with bicuculline, the potential 
for S44819 to produce repetitive firing. Submaximal (40 %) control fEPSPs (elicited at 
0.033 Hz) were recorded for 10 min. to establish consistent controls. In all cases (n = 3), 
the bath application of bicuculline (10 µM) caused clear repetitive firing of the fEPSP in 
response to a single electrical stimulation of the Schaffer collateral pathway (n = 3; Figure 
8Aiii). By contrast, S44819 (10 µM) was inert in this respect (n = 3; Figure 8Aii, suggesting 
that S44819 is devoid of pro-convulsant activity. In support, in mice S44819 was not pro-
convulsant, nor did it reduce the threshold for pentylene-tetrazol to induce convulsions 
(Gacsalyi et al., 2017). 
The synaptic plasticity underlying hippocampal LTP is considered a putative 
electrophysiological correlate of the processes underlying certain forms of learning and 
memory (Neves et al., 2008). Previous studies have demonstrated α5-GABAAR NAMs to 
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enhance hippocampal CA1 neuron LTP (Atack, 2011). To investigate whether S44819 
similarly influenced this form of synaptic plasticity we recorded fEPSPs from mouse CA1 
neurons. Again, submaximal (40 %) control fEPSPs (0.033 Hz) were recorded for 10 min. 
We previously reported that a 4-pulse theta burst stimulus (4-TBS) protocol induced 
maximal LTP, whereas a 3-pulse protocol (3-TBS) was submaximal (Zhang et al., 2013). 
In agreement, delivery of a 4-TBS induced a robust form of LTP, determined 50 min post 
the TBS (fEPSP slope = 195 ± 10% of control, n = 9), whereas that produced by a 3-TBS 
was significantly less effective (fEPSP slope = 124 ± 6 % of control; n = 6) (Figures 8B, C). 
S44819 (0.3 µM) greatly increased the fEPSP slope induced by a 3-TBS at 60 min after 
the TBS, (191 ± 14 % of control; n = 4) ----Figures 8B, C. In conclusion, for hippocampal 
CA1 neurons S44819 (10 µM) did not induce repetitive firing, but enhanced this form of 
synaptic plasticity (LTP) at a much lower concentration (300 nM). 
 
3.6) Effects of S44819 on learning and memory. 
In male rats, S44819 (0.1 -1 mg/kg p.o.) given 120 min prior to the acquisition trial in the 
object recognition assay increased the time spent investigating the novel object over the 
familiar object when assessed 24 h later (Figure 9A). Other dosage regimes of the drug 
were not tested. In the eight–arm radial maze, S44819 (1 and 3 mg/kg i.p.) was given 
simultaneously with scopolamine 30 min prior to the start of the test trial. S44819 
significantly diminished the marked increase in total errors induced by scopolamine (Figure 
9B). In both paradigms the effects of S44819 appeared dose-dependent.  
 
4. DISCUSSION 
This study describes the properties of S44819, a novel, potent, selective and competitive 
inhibitor of α5-GABAARs. Drugs previously reported to selectively impair the function of α5-
GABAARs do so by binding to the benzodiazepine site, located between the α and the γ 
subunit, to produce a negative allosteric effect and are classed as NAMs (Atack, 2011; 
Olsen and Sieghart, 2008; Rudolph and Möhler, 2014). Drugs such as L655,708 and 
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Ro4938581 exhibit binding selectivity, whereas others have similar binding affinities for 
most GABAAR isoforms, but are functionally selective NAMs e.g. α5IA (Atack, 2011). By 
contrast, evidence is presented here that S44819 competes with the neurotransmitter 
GABA for a binding site on the α5-GABAAR. Furthermore, the selectivity for this receptor 
isoform is governed by key amino acids residues in loop F of the α5 subunit. Note these 
amino acids are distinct from those α-subunit residues important for benzodiazepine 
binding. However, in common with known α5-GABAAR NAMs, S44819 exhibited pro-
cognitive activity in rodent behavioural studies.  
S44819 produced a potent inhibition of both the GABA-induced response (reported 
by a membrane potential-sensitive dye) and the GABA-evoked current mediated by 
recombinant α5-GABAARs expressed in HEK293 cells. A Schild-plot analysis of the effect of 
S44819 on the GABA concentration-response relationship suggested that S44819 is a 
competitive inhibitor of α5-GABAARs. In agreement, S44819 displaced the specific binding 
of the GABAAR agonist 3H-muscimol to recombinant α5-GABAARs, but in contrast to known 
selective α5-GABAAR NAMs, had no effect on the specific binding of the benzodiazepine 
3H-flumazenil. Computer modelling and site-directed mutagenesis implicated a role for the 
variable, NH2-terminal segment of loop-F of the α subunit in determining the 
pharmacological profile of structurally-related novel tricyclic compounds (Mihalik et al., 
2017). However, as inhibitory potency varied both with the compound tested and with the 
GABAAR isoform under study, it was important to now characterize S44819 in this respect. 
Significantly, in both the membrane potential dye and in the voltage-clamp assays the 
inhibitory potency of S44819 was markedly reduced upon mutation of the NH2-terminal 
segment of loop-F of the α5 subunit. Collectively, the data summarized above indicate that 
in common with other compounds containing an oxazolo-2,3 benzodiazepine scaffold 
(Mihalik et al., 2017), S44819 docks in the L-shaped GABA binding pocket (Bergmann et 
al., 2013) and an important element of the GABAAR isoform selectivity of the drug is an 
interaction with the variable segment of Loop-F of the α-subunit. 
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To investigate in mouse hippocampal slices the native GABAAR-isoform selectivity 
of S44819 we deliberately used a relatively high concentration (10 µM) of the inhibitor. This 
concentration of S44819 suppressed the tonic current mediated by extrasynaptic α5-
GABAARs (Caraiscos et al., 2004), but had no effect on the amplitude of mIPSCs mediated 
by synaptic GABAARs, whereas bicuculline blocked both phasic and tonic inhibition. 
Although most α5-subunits are expressed extrasynaptically, EM studies reveal them to be 
present within certain synapses of hippocampal pyramidal cells (Serwanski et al., 2006), 
with their location governed by the anchoring protein radixin (Hausrat et al., 2015). Indeed, 
a proportion of inhibitory phasic events with relatively slow kinetics, which in some neurons 
are sensitive to L655,708, an α5-GABAAR NAM, have been reported (Capogna and Pearce, 
2011; Prenosil et al., 2006; Salesse et al., 2011; Zarnowska et al., 2009). However, such 
events are primarily evident under conditions, which permit multi-vesicular GABA release 
(electrically evoked [e] IPSCs, or spontaneous [s] IPSCs). Therefore, the lack of effect of 
S44819 on mIPSCs (recorded in tetrodotoxin to block presynaptic action potentials) 
reported here is not unexpected. For thalamic VB neurons S44819 (10 µM) had no effect on 
the mIPSC amplitude mediated by synaptic GABAARs (α1β2γ2), or on the tonic current due 
to extrasynaptic α4β2δ receptors (Belelli et al., 2005; Peden et al., 2008), observations that 
further emphasise the α5-GABAAR selectivity of the drug. 
Therefore, in brain slice experiments S44819 is highly selective for extrasynaptic α5-
GABAARs. There are several factors that may contribute to this selectivity: 1) The GABAAR 
subunit selectivity evident from our studies on recombinant GABAARs; 2) Given the 
competitive nature of the antagonism, the marked difference between synaptic (≥ 10 µM 
(Jones and Westbrook, 1995; Karayannis et al., 2010; Maconochie et al., 1994)), and extra-
synaptic concentrations of GABA (≤ 2 µM, (Lerma et al., 1986; Wlodarczyk et al., 2013)); 3). 
A possible greater affinity of GABA for thalamic δ-GABAARs c.f. CA1 α5βγ2 GABAARs, 
coupled with an element of subunit selectivity, resulting in a clear differential effect of 
S44819 to block the hippocampal tonic current. However, note that in contrast to thalamus, 
the hippocampal experiments were conducted after treatment with vigabatrin to raise local 
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GABA concentrations. 4) The properties of native synaptic and extrasynaptic GABAARs 
may not be faithfully replicated by their recombinant counterparts expressed in cell lines.  
The brain slice studies were performed on “quiescent”, non-stimulated slices. However, we 
previously showed that physiological frequencies of presynaptic stimulation in the thalamus 
produced synaptic spill-over of GABA causing a large increase in the tonic current and a 
considerable prolongation of phasic inhibition (Herd et al., 2013). Given that S44819 is a 
competitive antagonist, equivalent studies for the hippocampus e.g. using TBS frequencies 
of stimulation would be of interest. Furthermore, a recent report identified a large tonic 
current mediated by α5-GABAARs in a sub-population of central amygdala neurons that was 
insensitive to gabazine, but was inhibited by picrotoxin and by L-655,708, an α5-GABAAR 
selective NAM, suggesting that these receptors spontaneously conduct anions (Botta et al., 
2015). Clearly, it would be of future interest to determine the effect of S44819 on such 
neurons to establish whether it differentiates between these extrasynaptic α5-GABAARs of 
hippocampus and amygdala. 
GABAAR antagonists such as bicuculline do not exhibit GABAAR isoform selectivity and 
consequently are pro-convulsant. As expected, in the hippocampus bicuculline inhibited 
both synaptic and extrasynaptic GABAARs and consequently produced repetitive firing. 
However, in contrast, relatively high concentrations of S44819 (10 µM) did not inhibit 
synaptic GABAARs and did not produce repetitive firing. Indeed, in mice behaviourally-
active doses of S44819 are not pro-convulsant, nor do they reduce the dose of pentylene-
tetrazol required to induce convulsions (Gacsályi et al., 2017). Selective α5-GABAAR NAMs 
facilitate hippocampal LTP (Atack, 2011). Similarly, a low concentration (300 nM) of S44819 
enhanced sub-maximal LTP of hippocampal CA1 neurons. Such effects on synaptic 
plasticity may contribute to the pro-cognitive actions of this compound. The effect on LTP, 
coupled with a lack of pro-convulsant activity c.f. bicuculline, further suggests that in 
hippocampal CA1 neurons S44819 acts as a selective inhibitor of α5-GABAARs. This 
selective effect on hippocampal synaptic plasticity warranted assessment of the pro-
cognitive potential of S44819. 
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A prominent involvement of α5-GABAARs in object recognition memory is well established. 
Administration of an α5-GABAAR positive allosteric modulator reduced the preference for 
the novel object, whereas α5-GABAAR inhibitors enhanced it (Ling et al., 2015; Milic et al., 
2013; Redrobe et al., 2012). In the version of the test used here, in rats S44819 
administered before the start of the acquisition trial effectively enhanced novel object 
preference measured 24 h later. The brain circuits that underlie novel object recognition in 
the rat are primarily within the perirhinal and entorhinal cortices. (Barker and Warburton, 
2011; Brown and Banks, 2015; Keene et al., 2016; Kinnavane et al., 2014). The role of tonic 
inhibition in these brain regions has not been studied in detail. However, mRNA expression 
studies in models of temporal epilepsy indicate that the molecular components of tonic 
inhibition are expressed in these cortical regions and show marked changes upon exposure 
to convulsive agents, suggestive of functional relevance (Drexel et al., 2013).  
The radial maze paradigm used here tests spatial working memory in an appetitive task. 
This test prominently involves the hippocampus, where the relevance of α5-GABAAR 
mediated tonic inhibition for the activation of principal neurons is well documented (Bonin et 
al., 2007; Caraiscos et al., 2004). Accordingly, S44819 was effective in ameliorating the 
profound deficit of working memory evoked by an acute injection of scopolamine. A likely 
mechanism underlying this effect of S44819 is the lowering of the firing threshold of CA1 
principal neurons, thereby enabling cholinergic triggering of hippocampal network 
oscillations (Cobb and Davies, 2005; Fisahn et al., 1998; Huerta and Lisman, 1995) in the 
face of inhibition by scopolamine. We have now reported a further characterisation of the 
behavioural actions of S44819 in preclinical models (Gacsályi et al., 2017). Consistent with 
these behavioural investigations, pharmacokinetic studies in rodents reveal S44819 to 
achieve active brain concentrations (brain:plasma ratio of 1:2 for male mice and 1:4 for 
male rats), with an appropriate time course (Gacsályi et al., 2017). Importantly, in clinical 
studies the EEG signal evoked by transcranial magnetic stimulation of the human neocortex 
indicated an enhancement of neuronal excitability after treatment with S44819 (Darmani et 
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al., 2016). Thus, in humans S44819 similarly reaches the CNS in concentrations sufficient 
to elicit a biological response.  
In conclusion, S44819 is a selective, competitive, inhibitor of extra-synaptic α5-GABAARs 
and provides a new mechanistic tool to elucidate the role of α5-GABAARs in neuronal 
signaling and behavior. Although acting by a distinct mechanism to known α5-GABAAR 
NAMs, in common with such drugs S44819 exhibits pro-cognitive activity in rodent 
behavioral studies. Given the potential for α5-GABAAR inhibitors to treat cognitive disorders 
(Atack, 2011) and to improve functional recovery following a stroke (Clarkson et al., 2010; 
Lake et al., 2015), these studies reveal an alternative site on the GABAAR to target for 
therapeutic exploitation. Indeed, S44819 is currently commencing Phase 2 clinical trials.  
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LEGENDS TO THE FIGURES 
 
Figure 1: S44819 selectively inhibits α5-GABAARs. The effect of S44819 on the GABA-
induced response mediated by GABAAR isoforms, stably expressed in HEK293 cells, was 
investigated by use of the FLIPR dye assay. A.) The effect of S44819 on the response to 
GABA (1.6 µM, EC30-50) was recorded from HEK cells stably expressing, α1 (●), α2 (■), α3 
(▲) or α5 (▼) - GABAAR subunits together with β2 and γ2 subunits. Data were expressed 
as a percentage of the control GABA response and represent the results of 3, 2, 4 and 3 
independent experiments for α1-, α2-, α3-, α5-GABAARs, respectively. Data represent the 
mean ± S.E.M. n = 3 - 12 per point. B.) GABA concentration-response curves obtained from 
cells expressing α5β2γ2 GABAARs in the presence of vehicle (●), 100 (■), 300 (▲), 1000 
(▼), 3000 (◆) and 10000 (□) nM S44819. Data are mean ± S.E.M, n = 3 - 21/group, 
collected from seven independent studies. Values for GABA EC50 were estimated by non-
linear regression with a least squares fit in Graphpad Prism v.6.0f.  
 
Figure 2: S44819 does not inhibit the activation of α5-GABAARs by etomidate. The 
FLIPR dye assay was used to investigate the putative inhibitory effect of S44819 (◆), 
gabazine (▲) and bicuculline (●) on the etomidate (30 µM) - evoked response elicited from 
HEK293 cells stably expressing α5β2γ2 GABAARs. Whereas bicuculline produced a 
concentration-dependent inhibition of the etomidate-evoked response, both S44819 and 
gabazine were relatively ineffective in this respect. Data were expressed as a percentage of 
the etomidate (30µM) – evoked control response (□). Data give the mean ± S.E.M. and are 
representative of two independent experiments, n = 3/point except for the control stimulus 
where n = 10.  
 
Figure 3: S44819 displaces the specific binding of 3H-muscimol, but not 3H-flumazenil 
to α5-GABAARs. Radio-ligand binding studies were performed with membranes prepared 
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from HEK293T cells transiently expressing α5β3γ2 GABAARs. A.) Displacement of 3H-
muscimol by S44819. Data are the mean ± S.E.M. n = 6 - 9/point and are representative of 
two independent experiments. B) S44819 (▲) does not displace 3H-flumazenil. Note the 
potency of the reference compound Ro4938581 (■) - (Knust et al., 2009). The data 
represent the means ± S.E.M., n= 4/point and are representative of two independent 
experiments. 
 
Figure 4: The inhibitory effect of S44819 is governed by α subunit F loop residues. 
FLIPR dye studies were performed in HEK293 cells stably expressing GABAAR β2 and γ2 
subunits
 
and transiently transfected with the WT α5 subunit (●) or an α5 subunit engineered 
to incorporate the α2 subunit F loop sequence (▲), that replaces the native α5 F-loop 
sequence (α5-LFα2) - (Mihalik et al., 2017). Although the F loop mutation had little effect on 
the GABA concentration response curves (not shown), it greatly reduced the inhibitory 
effect of S44819. The inset shows the amino acid sequence modifications to the α5 subunit 
F loop (shaded in grey). Data give the mean ± S.E.M, n = 3/group, and are representative of 
two independent studies.  
 
Figure 5: S44819 selectively inhibits GABA-evoked currents mediated by α5-
GABAARs, a specificity governed by α5 subunit loop-F residues. The bath application 
of S44819 (30 nM) potently inhibited GABA-evoked whole-cell currents mediated by α5β2γ2 
GABAARs transiently expressed in HEK-293 cells (●). By contrast, this concentration of 
S44819 had no effect on equivalent GABA-evoked responses mediated by α2β2γ2 
receptors (■), or on recombinant receptors engineered to express a mutant α5 subunit (α5-
LFα2)β2γ2 (▼)], where key amino acid residues in the loop F region have been exchanged 
to the equivalent loop F residues of the GABAAR α2 subunit (see Figure 4). The graph 
illustrates the time course of the effect of S44819 on GABA-evoked currents, with time = 0 
indicating the time from switching from control saline, to a solution containing S44819 (30 
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nM). Note there is an ~ 60 s perfusion lag-time required before the drug enters the 
recording chamber. For each experiment, at least 3 control GABA (100 µM; transiently 
applied by pressure for 50 ms from a local pipette once per min.) - evoked currents were 
recorded, with their amplitudes not varying by more than 10%, before S44819 (30 nM) was 
bath applied. The current amplitudes were normalized with respect to the first control 
amplitude. The mean normalized ± S.E.M. data were derived from 3 - 5 cells for each 
condition. The inset depicts representative GABA-evoked currents mediated by α5β2γ2 
GABAARs prior to and after the application of S44819 (30 nM). 
 
Figure 6: Selective inhibition of the GABA-mediated tonic current of mouse CA1 
pyramidal neurons by S44819. A.). A representative trace of a whole-cell voltage-clamp 
recording from a mouse CA1 pyramidal neuron (previously incubated in vigabatrin- see 
Methods), demonstrating that S44819 (10 µM) inhibits the majority of the tonic current in 
these neurons, as evidenced by the modest additional effect of bicuculline (30 uM) when 
co-applied with S44819 (10 µM). The broken horizontal lines illustrate the mean holding 
current in control, in the presence of S44819 and in the presence of S44819 + bicuculline. 
Inspection of the trace reveals S44819 to produce a clear outward current, but that the 
mIPSCs are still evident, whereas they are abolished by the subsequent addition of 
bicuculline. B.) In a paired recording a more detailed analysis of phasic inhibition revealed 
S44819 (10 µM) to have no effect on the amplitude of the representative ensemble 
averages of mIPSCs recorded before (black trace) and after (grey trace) the bath 
application of S44819 (10 µM). C. D.) Bar graphs (mean ± S.E.M.) summarizing the effects 
of S44819 (10 µM) and of bicuculline (30 µM) + S44819 (10 µM) upon C) the tonic current 
(n =3 neurons) and D) of S44819 (10 µM) upon the mIPSC peak amplitude (n = 5 neurons). 
 
Figure 7: S44819 has no effect on the tonic, or the phasic inhibitory currents 
(mIPSCs) of thalamocortical neurons A). A representative trace of a whole-cell voltage-
clamp recording from a ventrobasal (VB) neuron demonstrating that S44819 (10 µM) does 
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not produce an outward current i.e. it does not inhibit the resident tonic current in these 
neurons. The subsequent application of bicuculline (30 µM) produced an outward current 
and abolished the mIPSCs. The broken horizontal lines illustrate the mean holding current 
before and during S44819 and after S44819 + bicuculline. B.) S44819 (10 µM) had no 
effect on the properties of synaptic GABAARs, as illustrated by the representative ensemble 
averages of mIPSCs recorded before (black trace) and after (grey trace) the bath 
application of the drug. C, D). Bar graphs (mean ± S.E.M.) summarizing the effects of 
S44819 (10 µM) and of bicuculline (30 µM) on C) the tonic current (n = 4) and D) of S44819 
(10 µM) on the mIPSC the peak amplitude (n = 4). 
 
Figure 8: S44819 does not produce repetitive firing, but facilitates hippocampal CA1 
long-term potentiation (LTP). A.) Illustrated are individual field excitatory postsynaptic 
potential (fEPSPs) recorded from the dendritic field of mouse hippocampal CA1 neurons. 
The fEPSPs are elicited by electrical stimulation of the Schaffer Collateral pathway (once 
every 30 sec.) and are from a single representative experiment of 3 separate experiments. 
Ai) A control fEPSP, Aii) a fEPSP in the presence of S44819 (10 µM) and Aiii) a fEPSP in 
the presence of bicuculline (10 µM). Note this relatively high concentration of S44819 had 
no effect on the fEPSP, whereas bicuculline caused clear repetitive firing in response to a 
single electrical stimulus. B.) For the LTP experiments the slope of the fEPSP is plotted as 
a function of time before and after delivery of a 3- or 4-pulse theta burst stimulation (-TBS), 
delivered at t = 10 min. The 3-TBS is designed to induce a submaximal form of LTP (●), c.f. 
that produced by the 4-TBS paradigm (●). S44819 (300 nM) clearly enhanced the 
submaximal LTP induced by the 3-TBS (●). Note S44819 was present for the 10 min prior 
to delivery of the 3-TBS. Each time point (one every 30 sec.) represents the mean ± s.e.m. 
of 4 – 9 independent experiments. C.) The histogram compares the magnitude of LTP 
(%age of the control fEPSP slope determined at 60 min. i.e. 50 min post the TBS) for 
control 4-TBS (black), control 3-TBS (dark grey) and 3-TBS + 300 nM S44819 (light grey). 
Each bar represents the mean ± S.E.M. of 4 - 9 independent experiments. A one-way 
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ANOVA showed significant differences between treatments (p = 0.0002). A post hoc Tukey 
HSD multiple comparison test revealed a significant difference between the magnitude of 
LTP produced by a) the control 3-TBS and the control 4-TBS p = 0.001 **, b) between the 
control 3-TBS and the 3-TBS + S44819 p = 002* with c) no significant difference between 
the 4-TBS and the 3-TBS + S44819 (p = 0.961). 
 
Figure 9: The pro-cognitive efficacy of S44819. A.) A histogram illustrating the 
performance of male rats in the object recognition test assessed 24 h after the first 
exposure (acquisition) to two identical objects. S44819 (0.1, 0.3 and 1mg/kg nano F3), or 
vehicle (lipoïd S100/trehalose, 40%/60%, w/w) were given p.o. 120 min before the 
acquisition trial. Data are expressed as the discrimination index [DI] = (N-F/N+F), where N 
is the time spent investigating the new object and F is the time spent investigating the 
familiar object). 1-way ANOVA F(3,34) = 7.666 , p = 0.0005, followed by Dunnett‘s test for 
multiple comparisons, *p = 0.0352, *** p = 0.0001. B.) S44819 ameliorates the impairment 
of spatial working memory caused by scopolamine. Scopolamine hydrobromide (0.25 
mg/kg), or saline were injected s.c., immediately followed by the i.p. administration of either 
S44819 (1 and 3 mg/kg) or vehicle only (0.4 % methyl cellulose w/v) 30 min before the start 
of the test. The total error counts are shown, mean ± S.E.M., n = 9 - 10 rats/group ### p = 
0.0001 compared to the group (veh/veh) not receiving scopolamine, Man-Whitney U-test. 
To evaluate the effect of S44819 on the scopolamine-impaired performance c.f. the vehicle 
treated group that received scopolamine, the Kruskall-Wallis test H(3,30) =26.722, p = 0, 
followed by Dunn’s multiple comparisons test, p = 0.0332, *** p = 0.0001 was used. 
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Table 1: The GABAAR subtype selectivity of S44819. The subtype selectivity of S44819 was 
determined by use of the FLIPR assay to determine the inhibitory effect of S44819 on the GABA 
(1.6 µM) - induced depolarisation of HEK293 cells stably expressing recombinant GABAARs.  
 
Receptor 
isoform 
Geometric mean of 
IC50 (nM) 
95% confidence interval 
[nM] 
N 
α1β2γ2
      
 
2378  1319 to 4285  3  
α2β2γ2
       
  
N.D.  -  2  
α3β2γ2
       
 
3695  1752 to 7793  4  
α5β2γ2
   
 
585  386 to 886  3 
    
N.D. = could not be determined 
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All current, selective, inhibitors of α5-GABAARs bind to the “benzodiazepine site”. 
 
S44819 acts via a unique site on the α5-GABAAR to competitively inhibit GABA binding.  
 
S44819 inhibits mouse hippocampal tonic, but not phasic inhibition & facilitates LTP. 
 
In rats S44819 enhanced novel object recognition & spatial working memory. 
 
This novel α5-GABAAR site offers a new target to treat cognitive disorders & stroke. 
 
S44819 has successfully completed a phase1 clinical trial. 
 
